An estimated 150 million people worldwide are chronically infected with HCV

From Chemistry to Cures

More than 350,000 people die every year from HCV-related liver diseases

From Chemistry to Cures

The CDC estimated approximately 3.2 million people
in the U.S. are chronically infected with HCV

From Chemistry to Cures

ABOUT ENANTA

We are a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Learn more about us.

Our Vision

Our primary objective is to become a leader in the field of viral infections and liver diseases.

Our Research

We are pursuing validated targets within the HCV and non-alcoholic steatohepatitis field that specifically address the unmet medical needs for the treatment for these diseases. Learn more.